Trial Information - Phase III
postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Disease Specifics: m(HER2-)
Protocol ID: I3Y-MC-JPEF
Sponsor: Eli Lilly And Company
Status: OPEN TO ENROLLMENT
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
